Medicus Pharma director granted 50,000 stock options

Medicus Pharma Ltd. director Patrick J. Mahaffy reported receiving a stock option grant for 50,000 underlying common shares.

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Patrick J. Mahaffy reported receiving a stock option grant for 50,000 underlying common shares. The option carries an exercise price of $0.36 per share, was granted on June 3, 2026, and is scheduled to vest quarterly in four equal installments over one year. The option expires on June 3, 2031, and represents a compensation-related award rather than an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider MAHAFFY PATRICK J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 50,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

Key Figures

Option grant size: 50,000 options Exercise price: $0.36 per share Underlying shares: 50,000 common shares +4 more

7 metrics

Option grant size 50,000 options Stock Option (right to buy) granted to director

Exercise price $0.36 per share Conversion or exercise price of option

Underlying shares 50,000 common shares Shares underlying the stock option grant

Transaction price per option $0.00 Grant price, indicating compensation award (code A)

Grant date June 3, 2026 Date option was granted to Patrick J. Mahaffy

Expiration date June 3, 2031 Option expiration if not exercised earlier

Vesting schedule Quarterly over one year Four equal installments following June 3, 2026 grant

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 0.3600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2031-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest quarterly financial

"The option is scheduled to vest quarterly in four equal installments over one year."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medicus Pharma (MDCX) report for Patrick J. Mahaffy?

Medicus Pharma disclosed that director Patrick J. Mahaffy received a stock option grant for 50,000 underlying common shares. The award was reported as a derivative transaction on a Form 4, reflecting a compensation-related acquisition rather than an open-market trade in the company’s stock.

What are the terms of Patrick J. Mahaffy’s new stock options at Medicus Pharma (MDCX)?

The stock option gives Patrick J. Mahaffy the right to buy 50,000 Medicus Pharma common shares at an exercise price of $0.36 per share. The option was granted on June 3, 2026, and is scheduled to expire on June 3, 2031, if not exercised earlier under its terms.

How do Patrick J. Mahaffy’s Medicus Pharma (MDCX) options vest?

Patrick J. Mahaffy’s option grant is scheduled to vest quarterly in four equal installments over one year. This means the 50,000 underlying shares vest in four blocks of 12,500 each, aligning vesting with continued service over the year following the June 3, 2026 grant date.

Is Patrick J. Mahaffy buying or selling Medicus Pharma (MDCX) shares in this Form 4?

The Form 4 shows a grant of stock options, not an open-market buy or sell of shares. Code “A” and the zero-dollar transaction price per share indicate a compensation-related award, where Mahaffy acquires the option rights rather than immediately trading Medicus Pharma common stock.

How many Medicus Pharma (MDCX) options does Patrick J. Mahaffy hold after this transaction?

After this reported transaction, Patrick J. Mahaffy holds 50,000 stock options according to the Form 4. These options each relate to one underlying Medicus Pharma common share and are subject to the stated $0.36 exercise price, vesting schedule, and June 3, 2031 expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAHAFFY PATRICK J

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.36	06/03/2026		A		50,000		(1)	06/03/2031	Common Shares	50,000	$0	50,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Patrick J. Mahaffy	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)